increased risk of heart attacks in patients taking Telzir (fosamprenavir) for HIV

Health Canada is now warning about an increased risk of heart attacks in patients taking Telzir (fosamprenavir) for HIV.

Telzir is a protease inhibitor that's usually given with low-dose ritonavir and other HIV drugs.

Now some evidence suggests that Telzir increases cardiac risk.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter Canada includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get quote